journal article·2019-12-24

Nanomedicines Lost in Translation

Keegan Guidolin, Gang Zheng

ACS Nano· Volume 13· Issue 12
Publisher page

Abstract

Nanomedicines have historically struggled to find clinical relevance and to achieve translation successfully. In this Perspective, we discuss possible reasons for this difficulty and highlight several key features of nanomedicines that are often overlooked by biomedical engineers. We present the notion of clinical multifunctionality as distinct from multifunctionality as it is traditionally described at the nanoscale and emphasize its importance through examples of nanomedicines that have demonstrated emergent clinical multifunctionality once translated. We also describe a phenomenon in which clinical multifunctionality results in diagonal translation after a nanomedicine is adopted by clinicians to serve as a solution for a clinical problem that it was not designed to solve. Biomedical engineers can take advantage of these phenomena to assist in achieving clinical translation of new nanomedicines.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Surgery, University of Toronto, Toronto M5G 1L7, Canada

Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto M5G 1L7, Canada

Princess Margaret Cancer Centre, Toronto M5G 1L7, Canada

Department of Medical Biophysics, University of Toronto, Toronto M5G 1L7, Canada

Funding

Canada Research Chairs

References (41)

Show source-provided references
1. 10.1038/nrc156610.1038/nrc1566 ↗
2. 10.1002/wnan.121710.1002/wnan.1217 ↗
3. 10.1126/science.122633810.1126/science.1226338 ↗
4. 10.1039/C2CS15261D10.1039/C2CS15261D ↗
5. 10.1021/ja104317710.1021/ja1043177 ↗
6. FDA Approved Drug Products, 2019, https://www.accessdata.fda.gov/scripts/cder/daf/ (accessed October 23, 2019).
7. 10.1002/wnan.14310.1002/wnan.143 ↗
8. 10.1093/jjco/hyp07410.1093/jjco/hyp074 ↗
9. 10.1080/1061186080222842610.1080/10611860802228426 ↗
10. 10.1016/0022-1759(94)90012-410.1016/0022-1759(94)90012-4 ↗
11. 10.1002/ijc.2750210.1002/ijc.27502 ↗
12. 10.1158/1078-0432.CCR-05-163410.1158/1078-0432.CCR-05-1634 ↗
13. 10.2147/DDDT.S8802310.2147/DDDT.S88023 ↗
14. 10.1158/1078-0432.CCR-18-299010.1158/1078-0432.CCR-18-2990 ↗
15. 10.1016/j.leukres.2008.06.02810.1016/j.leukres.2008.06.028 ↗
16. 10.7150/thno.2167010.7150/thno.21670 ↗
17. 10.1158/1078-0432.CCR-16-319310.1158/1078-0432.CCR-16-3193 ↗
18. 10.1158/1078-0432.CCR-16-199010.1158/1078-0432.CCR-16-1990 ↗
19. Center for Drug Evaluation and Research Drug Products, Including Biological Products, that Contain Nanomaterials Guidance for IndustryU.S. Department of Health and Human Services, Food and Drug Administration: Rockville, MD, 2017; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/drug-products-including-biological-products-contain-nanomaterials-guidance-industry (accessed October 25, 2019).
20. 10.2147/JPR.S2789410.2147/JPR.S27894 ↗
21. 10.1016/j.arth.2019.04.04610.1016/j.arth.2019.04.046 ↗
22. 10.1016/j.jse.2019.04.05410.1016/j.jse.2019.04.054 ↗
23. 10.1093/pm/pnz10310.1093/pm/pnz103 ↗
24. 10.1097/PRS.000000000000569810.1097/PRS.0000000000005698 ↗
25. 10.1080/13696998.2019.162736310.1080/13696998.2019.1627363 ↗
26. 10.21037/jtd.2018.10.12410.21037/jtd.2018.10.124 ↗
27. 10.2147/JPR.S19387210.2147/JPR.S193872 ↗
28. 10.1016/S1470-2045(13)70162-110.1016/S1470-2045(13)70162-1 ↗
29. 10.1002/cncr.2472010.1002/cncr.24720 ↗
30. 10.1016/j.ygyno.2011.03.03610.1016/j.ygyno.2011.03.036 ↗
31. 10.1002/cncr.3032810.1002/cncr.30328 ↗
32. 10.1158/1078-0432.CCR-18-067310.1158/1078-0432.CCR-18-0673 ↗
33. 10.1002/jmri.2469110.1002/jmri.24691 ↗
34. 10.1002/mrm.2785310.1002/mrm.27853 ↗
35. Personalized Medicine. National Cancer Institute Dictionary of Cancer Terms; NIH: Bethesda, MD; https://www.cancer.gov/publications/dictionaries/cancer-terms/def/personalized-medicine (accessed November 23, 2019).
36. 10.1016/S0140-6736(19)31276-010.1016/S0140-6736(19)31276-0 ↗
37. 10.1016/j.nano.2019.10207610.1016/j.nano.2019.102076 ↗
38. 10.1002/smll.20130141710.1002/smll.201301417 ↗
39. Ventola C. L. · PT · 2017 · 42 · 742
40. 10.1002/wnan.610.1002/wnan.6 ↗
41. 10.1016/j.ejps.2018.11.01910.1016/j.ejps.2018.11.019 ↗